Neos Therapeutics Inc. (NASDAQ:NEOS) shares fell 2.8% during mid-day trading on Friday . The stock traded as low as $6.82 and last traded at $6.90, with a volume of 134,734 shares. The stock had previously closed at $7.10.

Several research firms have issued reports on NEOS. BMO Capital Markets began coverage on shares of Neos Therapeutics in a research report on Tuesday, June 28th. They issued an “outperform” rating and a $15.00 price target on the stock. Royal Bank Of Canada decreased their price target on shares of Neos Therapeutics from $33.00 to $29.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 17th. Zacks Investment Research cut shares of Neos Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 18th. Finally, Wells Fargo & Co. reiterated a “buy” rating on shares of Neos Therapeutics in a research report on Wednesday, May 18th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $21.75.

The stock’s market cap is $112.49 million. The firm has a 50-day moving average of $8.04 and a 200-day moving average of $9.37.

Neos Therapeutics (NASDAQ:NEOS) last issued its quarterly earnings data on Thursday, August 11th. The company reported ($1.65) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.16) by $0.49. The business had revenue of $1.49 million for the quarter, compared to analysts’ expectations of $1.48 million. On average, equities analysts anticipate that Neos Therapeutics Inc. will post ($5.38) earnings per share for the current year.

In related news, insider Juergen Martens bought 10,000 shares of Neos Therapeutics stock in a transaction dated Monday, June 13th. The shares were bought at an average cost of $9.90 per share, for a total transaction of $99,000.00. Following the completion of the transaction, the insider now owns 10,000 shares of the company’s stock, valued at $99,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Richard I. Eisenstadt bought 3,710 shares of Neos Therapeutics stock in a transaction dated Thursday, August 25th. The shares were bought at an average price of $6.82 per share, for a total transaction of $25,302.20. Following the completion of the transaction, the chief financial officer now directly owns 3,710 shares of the company’s stock, valued at approximately $25,302.20. The disclosure for this purchase can be found here.

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.